Angios biotech

Angios GmbH (Angios) was founded in 2021, headquartered in Innsbruck, Austria, as a biotechnology company. The company is committed to developing new therapies for challenging vascular diseases to improve the standard of care for diabetic retinopathy and utilizes laboratory-developed vascular organoid models.